Felix Cadenas-Lopez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Journal: Blood advances

Published: April 07, 2026

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

Journal: Blood advances

Published: January 20, 2026

Clinical, laboratory and genetic characteristics of VEXAS syndrome: a study on behalf of GESMD.

Clinical, laboratory and genetic characteristics of VEXAS syndrome: a study on behalf of GESMD.

Journal: Frontiers in immunology

Published: November 10, 2025

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Journal: Leukemia

Published: November 08, 2025

Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition.

Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition.

Journal: Blood advances

Published: October 29, 2025

Performance and Clinical Utility of Spanish Germline Genetic Testing Criteria for Hematologic Neoplasms Predisposition.

Performance and Clinical Utility of Spanish Germline Genetic Testing Criteria for Hematologic Neoplasms Predisposition.

Journal: Blood advances

Published: October 29, 2025

Mutational dynamics in patients with del(5q) MDS treated with lenalidomide prior to transfusion dependency-Molecular results from the Sintrarev clinical trial.

Mutational dynamics in patients with del(5q) MDS treated with lenalidomide prior to transfusion dependency-Molecular results from the Sintrarev clinical trial.

Journal: HemaSphere

Published: October 08, 2025

Use of mesenchymal stromal cells derived from the Wharton's jelly of human umbilical cord for treating patients with steroid-resistant graft versus host disease: predicting clinical response by a validated immunopotency assay.

Use of mesenchymal stromal cells derived from the Wharton's jelly of human umbilical cord for treating patients with steroid-resistant graft versus host disease: predicting clinical response by a validated immunopotency assay.

Journal: Scientific reports

Published: October 06, 2025

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Journal: Experimental hematology & oncology

Published: December 26, 2024

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.

Journal: Leukemia

Published: April 12, 2024

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.

Journal: The Lancet. Haematology

Published: March 16, 2024

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.

Journal: Blood

Published: January 05, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026